{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:02:11Z","timestamp":1790060531668,"version":"4.0.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["No. WSN-015 \u7f16\u53f7 WSN-015"],"award-info":[{"award-number":["No. WSN-015 \u7f16\u53f7 WSN-015"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor therapy has revolutionized the treatment of several malignancies, with improved survival, yet the accompanying myotoxicity has often been underestimated. We aimed to comprehensively and comparatively analyze the risk of myotoxicity associated with various ICIs using the FDA Adverse Event Reporting System database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data spanning from the first quarter of 2015 to the fourth quarter of 2024 were extracted from the U.S. Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was conducted using the reporting odds ratios (RORs) and corresponding 95% confidence intervals (CI) to identify potential safety signals associated with ICI-related myotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2015 to 2024, a total of 45,266 ICI-related myotoxicity reports were reported, of which 1,515 met the inclusion criteria, with a higher proportion of male patients (n = 904,59.7%). The median age was 69.4 years (interquartile range 49.9\u201377.6), and 46.2% of the patients were aged 65\u201385 years. A total of eight positive signals were identified, mainly myalgia [N = 366, reporting odds ratio = 1.25,95%confidence intervals (1.1\u20131.41), proportional reporting ratio = 1.25, \u03c72 = 12.55] and muscular weakness [N = 317, ROR = 1.53,95%CI (1.33\u20131.75), PRR = 1.53, \u03c72 = 37.75]. Among these events, polymyositis and rhabdomyolysis showed the highest proportions of fatal outcomes (42.86% and 38.83%, respectively). Among myositis-related reports, Triple M overlap syndrome was identified in 5.6% of cases, with fatal outcomes reported in 46.75% of these reports. In terms of onset time, 49.6% of the cases occurred within the first month of treatment (n = 303). The onset time of atezolizumab was the earliest (median 21 days), while durvalumab and Pembrolizumab showed longer or delayed risk windows (median 36 days and 34 days, respectively). And there were significant differences in the onset time of different ICI-related myotoxicity (P = 0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This FAERS-based pharmacovigilance study identified heterogeneous reporting signals and clinical patterns of ICI-associated myotoxicity. Most reported events occurred within the first 2\u00a0months of treatment, while myositis overlap syndromes, particularly the Triple M phenotype, were associated with higher proportions of fatal or life-threatening outcomes. These findings highlight the importance of early recognition and multidisciplinary monitoring of ICI-associated myotoxicity. Further clinical studies are warranted to validate these findings and clarify their underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1875873","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:11:35Z","timestamp":1790057495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Cuiping","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol. Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e210031","DOI":"10.1212\/wnl.0000000000210031","article-title":"Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy","volume":"103","author":"Beecher","year":"2024","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/bjsports-2024-108671","article-title":"Association of muscle strength and cardiorespiratory fitness with all-cause and cancer-specific mortality in patients diagnosed with cancer: a systematic review with meta-analysis","volume":"59","author":"Bettariga","year":"2025","journal-title":"Br. J. Sports Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"979116","DOI":"10.3389\/fimmu.2022.979116","article-title":"Tumor accomplice: t cell exhaustion induced by chronic inflammation","volume":"13","author":"Fang","year":"2022","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1488725","DOI":"10.3389\/fphar.2024.1488725","article-title":"The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline","volume":"15","author":"Fusaroli","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e8629","DOI":"10.7759\/cureus.8629","article-title":"A complex case of polymyositis overlapping with hypothyroid myopathy without underlying autoimmune thyroid disorder","volume":"12","author":"Garg","year":"2020","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cancers18071164","article-title":"Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a pharmacovigilance analysis of spontaneous reports","volume":"18","author":"Guzel","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ijc.35195","article-title":"The risk of treatment-related toxicities with PD-1\/PD-L1 inhibitors in patients with lung cancer","volume":"156","author":"Hu","year":"2025","journal-title":"Int. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: rhabdomyolysis -- an overview for clinicians","volume":"9","author":"Huerta-Alard\u00edn","year":"2005","journal-title":"Crit. Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.rdc.2024.02.003","article-title":"Immune checkpoint inhibitor-induced myositis","volume":"50","author":"Jayan","year":"2024","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3390\/life11101029","article-title":"Clinical efficacy and future prospects of immunotherapy in lung cancer","volume":"11","author":"Kinoshita","year":"2021","journal-title":"Life (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1212\/nxi.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1386362","DOI":"10.1080\/2162402x.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/01.bor.0000245721.02512.77","article-title":"Cancer and myositis: new insights into an old association","volume":"18","author":"Levine","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/0008-5472.Can-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1097\/cm9.0000000000003368","article-title":"Global, regional, and national lifetime risk of developing and dying from lung cancer in 2022: a population-based study in 185 countries","volume":"137","author":"Li","year":"","journal-title":"Chin. Med. J. (Engl)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/1759-7714.15272","article-title":"Safety and efficacy evaluation of personalized exercise prescription during chemotherapy for lung cancer patients","volume":"15","author":"Li","year":"","journal-title":"Thorac. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.2147\/ott.S255491","article-title":"Combination of immune checkpoint inhibitors with chemotherapy in lung cancer","volume":"13","author":"Liu","year":"2020","journal-title":"Onco Targets Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"586429","DOI":"10.3389\/fimmu.2021.586429","article-title":"Pharmacological and genetic inhibition of PD-1 demonstrate an important role of PD-1 in ischemia-induced skeletal muscle inflammation, oxidative stress, and angiogenesis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1283247","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"670784","DOI":"10.3389\/fneur.2021.670784","article-title":"The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1038\/s41598-021-90187-6","article-title":"Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC","volume":"11","author":"Mallet","year":"2021","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mus.28356","article-title":"Update on exercise in persons with muscle disease","volume":"71","author":"Mamarabadi","year":"2025","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s40425-019-0736-4","article-title":"Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors","volume":"7","author":"Matsubara","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/RHU.0000000000002211","article-title":"Mortality trends in polymyositis and dermatomyositis in Mexico: a general population-based study from 2000 to 2019","volume":"31","author":"Mendoza-Pinto","year":"2025","journal-title":"J. Clin. Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/bjsports-2021-105061","article-title":"Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies","volume":"56","author":"Momma","year":"2022","journal-title":"Br. J. Sports Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.3390\/jcm15103812","article-title":"Immune checkpoint inhibitor-associated immune-mediated nephropathy: a real-world pharmacovigilance study","volume":"15","author":"Mutis Alan","year":"2026","journal-title":"J. Clin. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e12532","DOI":"10.1111\/anec.12532","article-title":"Symptomatic arrhythmia in the form of multiple premature ventricular extrasystoles as the first symptom of polymyositis","volume":"23","author":"Peregud-Pogorzelska","year":"2018","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/jnd-200504","article-title":"Severe inflammatory myopathy in a pulmonary carcinoma patient treated with pembrolizumab: an alert for myologists","volume":"7","author":"Peverelli","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102033","DOI":"10.1016\/j.toxrep.2025.102033","article-title":"Immune checkpoint inhibitors: from friend to foe","volume":"14","author":"Rajak","year":"2025","journal-title":"Toxicol. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/annrheumdis-2019-eular.2707","article-title":"THU0628 immune-related adverse events induced by cancer immunotherapies. Big data analysis of 13,051 cases (immunocancer international registry)","volume":"78","author":"Ramos-Casals","year":"2019","journal-title":"Ann. Rheumatic Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","volume":"47","author":"Salem","year":"2026","journal-title":"Eur. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1597259","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho","year":"2025","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/jcsm.12828","article-title":"Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial","volume":"12","author":"Scott","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e200484","DOI":"10.1212\/nxi.0000000000200484","article-title":"Outcomes in patients with immune checkpoint inhibitor-related myopathy and prolonged Follow-Up","volume":"12","author":"Segal","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci. Rep."},{"key":"B50","first-page":"233","article-title":"Exercise therapy in muscle diseases: open issues and future perspectives","volume":"38","author":"Siciliano","year":"2019","journal-title":"Acta Myol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.55563\/clinexprheumatol\/q7mdjs","article-title":"Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment","volume":"41","author":"Sundarrajan","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1186\/s12885-025-14743-3","article-title":"Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system","volume":"25","author":"Tan","year":"2025","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5114\/reum\/168362","article-title":"Cardiac involvement in polymyositis and dermatomyositis: diagnostic approaches","volume":"61","author":"Trybuch","year":"2023","journal-title":"Reumatologia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1408586","DOI":"10.3389\/fcvm.2024.1408586","article-title":"Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity","volume":"11","author":"Wang","year":"2024","journal-title":"Front. Cardiovasc Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12865-022-00515-2","article-title":"NLRP3 inflammasome up-regulates major histocompatibility complex class I expression and promotes inflammatory infiltration in polymyositis","volume":"23","author":"Xia","year":"2022","journal-title":"BMC Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e70211","DOI":"10.1002\/pon.70211","article-title":"Experience and needs of immunotherapy for lung cancer patients: a meta-synthesis of qualitative studies","volume":"34","author":"Zhang","year":"2025","journal-title":"Psychooncology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:11:37Z","timestamp":1790057497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":57,"alternative-id":["10.3389\/fphar.2026.1875873"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1875873","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1875873"}}